Cartesian Therapeutics Stock (NASDAQ:RNAC)
Previous Close
$10.18
52W Range
$5.60 - $15.57
50D Avg
$7.82
200D Avg
$7.70
Market Cap
$311.15M
Avg Vol (3M)
$290.28K
Beta
0.46
Div Yield
-
RNAC Company Profile
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AARD | Aardvark Therapeutics, Inc. Common Stock |
| NTHI | Neonc Technologies Holdings, Inc. |
| GNFT | Genfit S.A. |
| AVTX | Avalo Therapeutics, Inc. |
| OBIO | Orchestra BioMed Holdings, Inc. |
| IVA | Inventiva S.A. |
| EPRX | Eupraxia Pharmaceuticals Inc. |
| MDWD | MediWound Ltd. |
| NAUT | Nautilus Biotechnolgy, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |